106:
97:
319:
25:
442:) to jointly develop a drug for hemophilia B, a long-lasting recombinant factor IX Fc fusion protein candidate, rFIXFc. This partnership was extended the following year to also include the development of a long-lasting recombinant factor VIII Fc fusion protein candidate, rFVIIIFc, for the treatment of hemophilia A.
438:, and marketing of specialty pharmaceuticals (ReFacto, Mimpara and Kineret®) was initiated in the Nordic region. In 2005, the research and development portfolio was expanded through the acquisition of Arexis, a Swedish biotech company, and the following year a partnership was formed with Syntonix (subsequently
499:
Sobi is an international specialty healthcare company dedicated to rare diseases with a focus on treatments in haematology, immunology and speciality care. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees; by 2020 the revenue was SEK 15.261 billion and there were
468:
projects as well as
Kiobrina into phase III were taken. The following year the first patient was enrolled in the phase 3 study for Kiobrina and data from the rFVIIIFc hemophilia phase I/II study were presented showing an approximately 1.7-fold increase in half-life compared with Advate. The company
452:
took the decision to enter final registration studies for the recombinant factor FIXFc. The company also received positive data regarding its
Kiobrina phase II program, an investigational enzyme replacement therapy to improve growth in preterm infants who receive pasteurized breast milk or infant
808:
396:
Sobi has been involved in the process development and manufacturing of recombinant protein drugs since the technology was first developed around 30 years ago, then as part of
877:
815:
882:
867:
58:
383:
445:
In 2008, an agreement with Amgen regarding the acquisition of the products
Kepivance and Stemgen as well as a global license for Kineret was signed
372:
725:
872:
476:
for ReFacto/Xyntha was extended until 2020 in addition to the agreement to return the co-promotion rights for the Nordic region for ReFacto to
887:
638:
862:
336:
761:
892:
487:
Guido
Oelkers was appointed President and CEO in May 2017, succeeding Geoffrey McDonough. Oelkers had previously been CEO of
371:
Sobi traces its origins to a subsidiary of Kärnbolaget
Aktiebolag Biokemisk Industri in the 1930s, which changed its name to
783:
553:
419:, a process development unit for protein drugs and a plasma product operation. In 2002 Sobi sold its plasma operation to
35:
561:
549:
206:
358:
76:
525:
44:
340:
696:
737:
541:
484:
initiated global pediatric clinical trials of their long-lasting hemophilia A and B product candidates.
505:
134:
572:. The company also market a portfolio of specialty and rare disease products for partner companies.
54:
50:
645:
612:
329:
171:
40:
464:, and Swedish Orphan Biovitrum AB (publ) was formed. In addition, the decisions to advance both
144:
529:
533:
552:, and the 2020 annual report shows a further six products as "pre-market" in the areas of
8:
423:
as part of efforts to concentrate operations on protein-based and small molecular drugs.
416:
287:
105:
670:
230:
96:
412:
251:
116:
856:
501:
130:
124:
461:
426:
In 2004, Biovitrum started to manufacture the active protein component for
557:
517:
481:
449:
439:
291:
256:
465:
435:
420:
397:
343: in this section. Unsourced material may be challenged and removed.
295:
415:
and MPM Capital Funds. Operations included a research unit focused on
457:
404:
388:
299:
192:
Treatments in the areas of haematology, immunology and specialty care
154:
403:
Biovitrum was formed in 2001 through the merger of several units of
318:
305:
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees.
24:
545:
521:
513:
178:
704:
537:
480:
for a payment of USD 47.4 M. The same year, the Sobi and partner
377:
509:
488:
477:
473:
460:
acquired
Swedish Orphan International Holding AB, a pioneer in
431:
408:
427:
218:
569:
845:
788:
565:
434:’s) ReFacto® and ReFacto/Xyntha® drugs for treatment of
267:
762:"Guido Oelkers appointed President and CEO at Sobi"
726:
Change of company name for
Biovitrum AB, 2010-06-21
411:) and spun off to a consortium of investors led by
809:"Report for the fourth quarter and year-end 2013"
854:
290:company dedicated to treatments in the areas of
39:, potentially preventing the article from being
878:Pharmaceutical companies established in 2001
633:
631:
629:
627:
625:
575:
883:Manufacturing companies based in Stockholm
868:Companies related to the Wallenberg family
104:
95:
59:reliable, independent, third-party sources
801:
622:
359:Learn how and when to remove this message
77:Learn how and when to remove this message
663:
607:
605:
603:
601:
599:
597:
595:
500:1,509 employees. The share is listed at
53:by replacing them with more appropriate
639:"Annual and Sustainability Report 2020"
613:"Annual and sustainability report 2022"
36:too closely associated with the subject
855:
776:
689:
873:Swedish companies established in 2001
592:
888:Companies listed on Nasdaq Stockholm
754:
341:adding citations to reliable sources
312:
18:
393:to become KabiVitrum in the 1970s.
13:
863:Pharmaceutical companies of Sweden
472:In 2012 the supply agreement with
469:also established a US subsidiary.
14:
904:
837:
738:"Spago Nanomedical AB (SPAGO-SS)"
508:. The company's products include
317:
34:may rely excessively on sources
23:
328:needs additional citations for
275:Footnotes / references
730:
719:
16:Swedish pharmaceutical company
1:
893:2006 initial public offerings
671:"Swedish Orphan Biovitrum AB"
585:
564:, acute graft failure (aGF),
298:and specialty care, based in
7:
580:Synagis (From Astrazeneca)
284:Swedish Orphan Biovitrum AB
90:Swedish Orphan Biovitrum AB
10:
909:
494:
448:In 2009, Sobi and partner
308:
576:Acquisitions and licenses
273:
263:
250:
240:
228:
216:
204:
196:
188:
161:
150:
140:
122:
112:
103:
94:
382:in 1951 and merged with
568:and chronic refractory
536:for several disorders;
814:. Sobi. Archived from
644:. Sobi. Archived from
582:Dova Pharmaceuticals
516:for the treatment of
784:"SOBI: Business Man"
337:improve this article
286:is an international
821:on 30 November 2014
242:Number of employees
91:
764:. Sobi. 4 May 2017
417:metabolic diseases
236:SEK 26.5 bn (2022)
224:SEK 52.5 bn (2022)
212:SEK 14.4 bn (2022)
200:SEK 18.8 bn (2022)
177:Bo Jesper Hansen (
89:
675:www.bloomberg.com
369:
368:
361:
288:biopharmaceutical
281:
280:
87:
86:
79:
900:
849:
848:
846:Official website
831:
830:
828:
826:
820:
813:
805:
799:
798:
796:
794:
780:
774:
773:
771:
769:
758:
752:
751:
749:
748:
734:
728:
723:
717:
716:
714:
712:
703:. Archived from
693:
687:
686:
684:
682:
667:
661:
660:
658:
656:
650:
643:
635:
620:
619:
617:
609:
502:Nasdaq Stockholm
392:
381:
364:
357:
353:
350:
344:
321:
313:
233:
221:
207:Operating income
131:Nasdaq Stockholm
108:
99:
92:
88:
82:
75:
71:
68:
62:
27:
19:
908:
907:
903:
902:
901:
899:
898:
897:
853:
852:
844:
843:
840:
835:
834:
824:
822:
818:
811:
807:
806:
802:
792:
790:
782:
781:
777:
767:
765:
760:
759:
755:
746:
744:
736:
735:
731:
724:
720:
710:
708:
695:
694:
690:
680:
678:
669:
668:
664:
654:
652:
648:
641:
637:
636:
623:
618:. June 1, 2023.
615:
611:
610:
593:
588:
581:
578:
497:
386:
375:
365:
354:
348:
345:
334:
322:
311:
277:
243:
229:
217:
209:
184:
170:Guido Oelkers (
164:
127:
83:
72:
66:
63:
48:
28:
17:
12:
11:
5:
906:
896:
895:
890:
885:
880:
875:
870:
865:
851:
850:
839:
838:External links
836:
833:
832:
800:
775:
753:
729:
718:
707:on 25 May 2021
688:
662:
651:on 25 May 2021
621:
590:
589:
587:
584:
577:
574:
496:
493:
413:Nordic Capital
367:
366:
325:
323:
316:
310:
307:
279:
278:
271:
270:
265:
261:
260:
254:
248:
247:
244:
241:
238:
237:
234:
226:
225:
222:
214:
213:
210:
205:
202:
201:
198:
194:
193:
190:
186:
185:
183:
182:
175:
167:
165:
162:
159:
158:
152:
148:
147:
145:Pharmaceutical
142:
138:
137:
128:
123:
120:
119:
114:
110:
109:
101:
100:
85:
84:
31:
29:
22:
15:
9:
6:
4:
3:
2:
905:
894:
891:
889:
886:
884:
881:
879:
876:
874:
871:
869:
866:
864:
861:
860:
858:
847:
842:
841:
817:
810:
804:
789:
785:
779:
763:
757:
743:
739:
733:
727:
722:
706:
702:
698:
692:
676:
672:
666:
647:
640:
634:
632:
630:
628:
626:
614:
608:
606:
604:
602:
600:
598:
596:
591:
583:
573:
571:
567:
563:
559:
555:
551:
547:
543:
539:
535:
531:
527:
523:
519:
515:
511:
507:
503:
492:
490:
485:
483:
479:
475:
470:
467:
463:
459:
454:
451:
446:
443:
441:
437:
433:
429:
424:
422:
418:
414:
410:
406:
401:
399:
394:
390:
385:
379:
374:
363:
360:
352:
342:
338:
332:
331:
326:This section
324:
320:
315:
314:
306:
303:
301:
297:
293:
289:
285:
276:
272:
269:
266:
262:
258:
255:
253:
249:
245:
239:
235:
232:
227:
223:
220:
215:
211:
208:
203:
199:
195:
191:
187:
180:
176:
173:
169:
168:
166:
160:
156:
153:
149:
146:
143:
139:
136:
132:
129:
126:
121:
118:
115:
111:
107:
102:
98:
93:
81:
78:
70:
60:
56:
52:
46:
42:
38:
37:
32:This article
30:
26:
21:
20:
823:. Retrieved
816:the original
803:
791:. Retrieved
787:
778:
766:. Retrieved
756:
745:. Retrieved
741:
732:
721:
709:. Retrieved
705:the original
700:
691:
679:. Retrieved
674:
665:
653:. Retrieved
646:the original
579:
498:
486:
471:
462:orphan drugs
455:
447:
444:
425:
402:
395:
370:
355:
346:
335:Please help
330:verification
327:
304:
283:
282:
274:
246:1,600 (2022)
231:Total equity
219:Total assets
151:Headquarters
113:Company type
73:
64:
49:Please help
33:
677:. Bloomberg
558:haemophilia
518:haemophilia
489:BSN Medical
482:Biogen Idec
450:Biogen Idec
440:Biogen Idec
387: [
376: [
292:haematology
257:Investor AB
857:Categories
747:2022-09-14
586:References
466:hemophilia
436:hemophilia
421:Octapharma
398:KabiVitrum
302:, Sweden.
296:immunology
163:Key people
51:improve it
41:verifiable
697:"History"
458:Biovitrum
456:In 2010,
453:formula.
405:Pharmacia
300:Stockholm
155:Stockholm
125:Traded as
55:citations
742:biotickr
546:Gamifant
522:Doptelet
514:Alprolix
430:’s (now
349:May 2020
268:sobi.com
189:Products
179:chairman
157:, Sweden
141:Industry
67:May 2020
538:Synagis
534:Kineret
504::
495:Company
309:History
264:Website
259:(34.7%)
197:Revenue
133::
45:neutral
825:25 May
711:25 May
655:25 May
510:Elocta
478:Pfizer
474:Pfizer
432:Pfizer
409:Pfizer
384:Vitrum
252:Parent
117:Public
819:(PDF)
812:(PDF)
793:6 May
768:6 May
681:7 May
649:(PDF)
642:(PDF)
616:(PDF)
428:Wyeth
407:(now
391:]
380:]
827:2021
795:2020
770:2020
713:2021
701:Sobi
683:2020
657:2021
570:gout
562:sHLH
550:pHLH
548:for
544:and
540:for
528:and
524:for
512:and
506:SOBI
373:Kabi
135:SOBI
43:and
566:ALS
554:PNH
542:RSV
532:;
530:CLD
526:ITP
339:by
172:CEO
57:to
859::
786:.
740:.
699:.
673:.
624:^
594:^
560:,
556:,
520:;
491:.
400:.
389:sv
378:sv
294:,
829:.
797:.
772:.
750:.
715:.
685:.
659:.
362:)
356:(
351:)
347:(
333:.
181:)
174:)
80:)
74:(
69:)
65:(
61:.
47:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
